| Identification | Back Directory | [Name]
1H-1,2,3-Triazole-4-carboxamide, 1-cyclopropyl-N-[1-[[1-(phenylmethyl)-1H-pyrazol-4-yl]methyl]-3-azetidinyl]- | [CAS]
1887193-58-9 | [Synonyms]
EPZ032597
1H-1,2,3-Triazole-4-carboxamide, 1-cyclopropyl-N-[1-[[1-(phenylmethyl)-1H-pyrazol-4-yl]methyl]-3-azetidinyl]- | [Molecular Formula]
C20H23N7O | [MOL File]
1887193-58-9.mol | [Molecular Weight]
377.44 |
| Hazard Information | Back Directory | [Uses]
EPZ032597 is a selective and noncompetitive SMYD2 inhibitor with an IC50 value of 16 nM. EPZ032597 is promising for research of pancreatic ductal adenocarcinoma[1][2]. | [References]
[1] Alshammari E, et al. Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer. World J Gastroenterol. 2022 Aug 7;28(29):3753-3766. DOI:10.3748/wjg.v28.i29.3753
[2] Thomenius MJ, et al. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS One. 2018 Jun 1;13(6):e0197372. DOI:10.1371/journal.pone.0197372 |
|
|